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M ucinous carcinoma (MC) of the breast is a rare and special type of malignancy with a substan-
tial amount of extracellular mucin.  The incidence of 
MC is 1-6% of all breast malignancies,  and the progno-
sis of the patients with MC is reported to be better than 
that of patients with invasive ductal cancer-no special 
type (IDC-NST) [1-3].  MC patients were also reported 
to tend to be elderly,  menopausal,  and have a high 
expression of hormone receptors and a low expression 
of human epidermal growth factor receptor 2 (HER2).  
MC is defined as having a mucinous component com-
prising > 50% of the lesion.  MC is divided into 2 groups,  
a pure type and a mixed type,  according to the presence 
of a concomitant area with typical infiltrating ductal 
carcinoma or the proportion of mucin; however,  a 
clear definition has not been established [1-6].
A large number of MC patients were analyzed using 
the Surveillance,  Epidemiology and End Results (SEER) 
database,  and these analyses revealed prognostic factors 
of MC patients [7 , 8].  However,  the long-term progno-
sis of MC patients in Japan has not been fully clarified.  
We conducted the present study determine whether the 
previously reported characteristics of MC patients can 
be applied to Japanese patients who underwent surgery 
during a > 30-year period at a single hospital.  We inves-
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Mucinous carcinoma (MC) of the breast is a rare and special type of malignancy,  with a substantial amount of 
extracellular mucin.  We compared the clinicopathological features and the long-term survival of MC patients 
with those of invasive ductal carcinoma-no special type (IDC-NST) patients,  and we examined prognostic fac-
tors of MC.  A total of 116 patients with mucinous carcinoma and 3,258 patients with IDC-NST who underwent 
surgery at our hospital (1977-2008) were enrolled.  The 10-year overall survival rate and breast cancer-specific 
survival rate (BSS) of the MC patients (88.3%,  93.7%) were both significantly higher than those of IDC-NST 
patients (81.6%,  85.0%) (p= 0.015,  p= 0.005,  respectively).  A Cox regression analysis demonstrated that MC 
tended to be an independent prognostic factor (hazard ratio 0.44,  p= 0.098).  The BSS of the MC patients with 
positive lymph node (LN) metastasis was significantly poorer than that of the patients without it,  by univariate 
analysis (p= 0.002).  The tumor size in the MC patients with positive LN metastasis (mean 3.2 cm) was signifi-
cantly larger than that in the patients without it (mean 1.9 cm) (p= 0.0004).  Although a Cox regression analysis 
revealed no independent factor,  MC patients with positive LN metastasis should be treated for advanced inva-
sive ductal breast cancer.
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tigated the long-term prognoses of these MC patients in 
a comparison with those of IDC-NST patients,  and we 
sought to identify prognostic factors for MC patients.
Patients and Methods
Of the 4,654 patients who underwent breast surgery 
at Oomoto Hospital (No. 0111442,  a medical corpora-
tion hospital in Okayama,  Japan) between February 
1977 and December 2008,  116 patients with MC and 
3,258 patients with IDC-NST were enrolled in this 
study.  The IDC-NST group consisted of 1,003 cases of 
the tubule-forming type,  1,045 cases of the solid type,  
and 1,210 cases of the scirrhous type according to the 
General Rules for Clinical and Pathological Recording 
of Breast Cancer issued by the Japanese Breast Cancer 
Society [9].  Patients with prior or simultaneous cancer 
of other organs or other breast cancer (ipsilateral or 
opposite breast) were excluded.
The clinicopathological factors of the MC group 
were evaluated in a comparison with those of the IDC-
NST patients.  The patients’ mammography (MG) find-
ings and ultrasonography (US) findings were catego-
rized based on the Breast Imaging-Reporting and Data 
System (BI-RADS) [10].  The tumor stages were classi-
fied based on the TNM (UICC) classification [11].  
Long-term prognoses were examined in 80 patients 
with MC and 2,813 patients with IDC-NST whose fol-
low-up periods after surgery were > 5 years.  We com-
pared the overall survival (OS) rate and the breast can-
cer-specific survival (BSS) rate of the MC group with 
those of the IDC-NST group.  The BSS of the MC 
patients was evaluated in relation to their lymph node 
(LN) metastasis and tumor sizes.  Patients with recur-
rence of MC were investigated in detail.  Prognostic 
factors for invasive ductal carcinoma (MC+IDC-NST) 
and MC were evaluated by a multivariate analysis (Cox 
regression).
All statistical analyses were performed with EZR 
(Saitama Medical Center,  Jichi Medical University,  
Saitama,  Japan),  which is a graphical user interface for 
R (The R Foundation for Statistical Computing,  
Vienna,  Austria) [12].  More precisely,  EZR is a modi-
fied version of R commander designed to add statistical 
functions frequently used in biostatistics.  The two 
patient groups’ OS curves and the BSS curves were 
determined and plotted by the Kaplan-Meier method.  
In general,  p-values < 0.05 by Fisher’s exact test,  the 
unpaired t-test,  log rank test,  and Cox regression pro-
portional hazards model were considered significant.
This study was approved by the Ethics Committee of 
Oomoto Hospital in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki and 
all subsequent revisions.
Results
The incidence of mucinous carcinoma was 3.43% of 
all of the invasive ductal cancers in this patient series 
during the study period.  The clinicopathological factors 
of the MC and IDC-NST groups are summarized in 
Table 1.  The MC patients (mean age 56.8 years old) 
were significantly older than the IDC-NST patients 
(mean age 54.0 years old).  The preoperative BI-RADS 
values of MG and US for malignancy of the MC cases 
were both significantly lower than those of the IDC-
NST cases (p = 0.001,  p < 0.001).  Breast-conserving 
surgery was performed more frequently for the MC 
patients than for the IDC-NST patients (p= 0.006).  The 
rate of positive LN metastasis in the MC group (15.2%) 
was significantly lower than that in the IDC-NST group 
(39.2%) (p < 0.001).  There were no significant differ-
ences in tumor size between the MC and IDC-NST 
patients.
The rate of positive estrogen receptor (ER) in the MC 
patients (81.7%) was significantly higher than that in the 
IDC-NST patients (68.2%) (p = 0.002).  Chemotherapy 
was performed less frequently for the MC patients than 
for the IDH-NST patients.  The rate of radiation treat-
ment rate in the total patient series was very low,  
because our hospital did not recommend radiation 
treatment for most of the patients who undergo mar-
gin-negative breast-conserving surgery in this cohort 
series until the General Rules for Clinical and 
Pathological Recording of Breast Cancer were issued in 
2005.
The OS and BSS of the MC and IDC-NST patients.
The 10-year OS (88.3%) of the MC patients was signifi-
cantly higher than that of the IDC-NST patients 
(81.6%) (p = 0.0148) (Fig. 1).  As illustrated in Fig. 2,  the 
10-year BSS of the MC patients (93.7%) was signifi-
cantly higher than that of the IDC-NST patients 
(85.0%) (p = 0.00488).  The Cox regression proportional 
hazards model for BSS (MC+IDC-NST) revealed that 
tumor size and positive LN metastasis were strong inde-
pendent prognostic factors (Table 2).  MC was an inde-
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pendent factor,  although not significantly (hazard ratio 
[HR] 0.44,  p = 0.098).
The BSS of the MC patients in relation to the clini-
cal factors. Of the 80 MC patients,  9 died (breast 
cancer,  n = 4; other disease,  n = 5).  The characteristics 
of the 4 MC patients with recurrence (1 local and 3 dis-
tant) are shown in Table 3.  All 4 of these patients had 
lymphovascular invasion,  and 3 of them had positive 
LN metastasis.
The BSS of the MC patients with positive LN metas-
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Table 1　 Clinicopathological factors of MC and IDC-NST
Factor Group MC IDC-NST p-value
n 116 3,258
Age Mean (SD) Years 56.79 (15.71) 53.98 (12.14) 0.015
Median Years 56 53
Menopause (%) No 46 (39.7) 1,453 (44.6)
Yes 70 (60.3) 1,805 (55.4) 0.298
Side (%) Left 62 (53.4) 1,753 (53.8) 1
Right 54 (46.6) 1,505 (46.2)
Subsites (%) 1. Nipple  9 (7.8) 181 (5.6) NA
2. Central portion 1 (0.9) 156 (4.8)
3. Upper-inner quadrant 41 (35.3) 948 (29.1)
4. Lower-outer quadrant 11 (9.5) 205 (6.3)
5. Upper-outer quadrant 45 (38.8) 1,473 (45.2)
6. Lower-outer quadrant 9 (7.8) 295 (9.1)
BI-RADS MG category (%) 2 ,3 ,4 28 (26.4) 436 (14.0) 0.001
5 78 (73.6) 2,676 (86.0)
BI-RADS US category (%) 2 ,3 ,4 38 (34.9) 445 (14.7) ＜0.001
5 71 (65.1) 2,584 (85.3)
Operative procedure (%) Breast conserving surgery 46 (39.7) 897 (27.5) 0.006
Mastectomy 70 (60.3) 2,361 (72.5)
Positive LN (%) No 84 (84.8) 1,884 (60.8) ＜0.001
Yes 15 (15.2) 1,217 (39.2)
Number of positive LN Mean (sd) Number 2.80 (1.90) 6.97 (9.29) 0.083
Tumor size (%) ＜2 cm 62 (53.4) 1,654 (51.2) 0.706
≧2 cm 54 (46.6) 1,576 (48.8)
Tumor size Mean (sd) cm 2.05 (1.30) 2.34 (1.94) 0.11
TNM stage (%) I 77 (66.4) 2,094 (64.3) ＜0.001
II 18 (15.5) 646 (19.8)
III 3 (2.6) 276 (8.5)
IV 0 (0.0) 81 (2.5)
Unknown 18 (15.5) 161 (4.9)
ER (%) Negative 20 (18.3) 974 (31.8) 0.002
Positive 89 (81.7) 2,089 (68.2)
PgR (%) Negative 35 (32.1) 1,303 (43.4) 0.023
Positive 74 (67.9) 1,702 (56.6)
Hormone therapy (%) No 45 (38.8) 1,244 (38.2) 0.923
Yes 71 (61.2) 2,014 (61.8)
HER2 (%) Negative 31 (96.9) 597 (86.1) 0.108
Positive 1 (3.1) 96 (13.9)
Chemotherapy (%) No 47 (40.5) 587 (18.0) ＜0.001
Yes 69 (59.5) 2,671 (82.0)
Radiation (%) No 115 (99.1) 3,197 (98.1) 0.724
Yes 1 (0.9) 61 (1.9)
MC,  mucinous carcinoma; IDC-NST,  invasive mucinous carcinoma of no special type; BI-RADS,  breast imaging-reporting and data sys-
tem; MG,  mammography; US,  ultrasound; LN,  lymph node; ER,  estrogen receptor; PgR,  progesterone receptor; HER2,  human epider-
mal growth factor 2; NA,  not applicable.
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Fig. 2　 The breast cancer-specific survival (BSS) rates of the MC 
and IDC-NST groups.
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Fig. 1　 The overall survival (OS) rates of the MC and IDC-NST 
groups.
Table 2　 Cox regression proportional hazards ratio of breast 
cancer-specific survival (IDC-NST+MC)
Factor Hazard ratio p-value
Tumor size of 2 cm or more 2.27 (1.84-2.80) 2.11E-14
Positive lymph node metastasis 4.83 (3.85-6.05) 0
Hormone therapy 1.09 (0.89-1.34) 0.4
Chemotherapy 1.17 (0.79-1.66) 0.38
MC vs IDC-NST 0.44 (0.16-1.17) 0.098
MC,  mucinous carcinoma; IDC-NST,  invasive mucinous carcinoma 
of no special type.
tasis was significantly lower than that of the MC 
patients without it (p = 0.0018) (Fig. 3).  The BSS of the 
MC patients with a tumor size ≥ 2 cm was lower than 
that of the MC patients with smaller tumor sizes,  but 
the difference was not significant (p = 0.156) (Fig. 4).  
Among the MC patients,  the tumor size (3.2 ± 1.7 cm,  
mean ± SD) in the patients with positive LN metastasis 
was significantly larger than the tumor size of the 
patients without positive LN metastasis (1.9 ± 1.2 cm,  
mean ± SD) (p = 0.0004) (Fig. 5).  The Cox regression 
proportional hazards model revealed no independent 
factor for BSS in the patients with MC in this series 
(Table 4).
Discussion
The results of our analyses demonstrated the follow-
ing: Regarding IDC,  (1) the OS and the BSS of the MC 
patients were significantly longer than those of the 
IDC-NST patients,  and (2) MC tended to be an inde-
pendent prognostic factor (HR 0.44,  p= 0.098).  Among 
the MC patients,  (1) the BSS of the patients with posi-
tive LN metastasis was significantly poorer than the BSS 
of the patients without positive LN metastasis; (2) The 
tumor size (mean 3.2 cm) in the MC patients with pos-
itive LN metastasis was significantly larger than that in 
the patients without positive LN metastasis (mean 
1.9 cm) (p = 0.0004); and (3) No independent prognos-
tic factor was found for MC patients by Cox regression 
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Fig. 3　 The BSS of the MC patients according to positivity of 
lymph node metastasis.
0 5 10 15 20 25 30
0.0
0.2
0.4
0.6
0.8
1.0
Years
B
re
as
t 
ca
nc
er
-s
pe
ci
fic
 s
ur
vi
va
l r
at
e
0
1
＜2 cm    n=46
≧2 cm    n=34
p=0.156 
Mucinous carcinoma Tumor Size
Fig. 4　 The BSS of the MC patients according to tumor size.
No Yes
Positive LN
Tu
m
or
 s
iz
e
0
1
2
3
4
5 p=0.0004
n=84
n=15
Mucinous carcinoma
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Table 4　 Cox regression proportional hazards ratio of breast 
cancer-specific survival (MC)
Factor Hazard ratio p-value
Tumor size of 2 cm or more 3.22 (0.31-32.00) 0.33
Positive lymph node metastasis 2.61 (0.22-30.68) 0.24
Hormone therapy 168000000.00 (0.00-Inf) 1
Chemotherapy 122000000.00 (0.00-Inf) 1
MC,  mucinous carcinoma.
analysis in this series.
The clinicopathological characteristics of the MC 
patients in this study were consistent with those previ-
ously reported.  Compared to the present IDC-NST 
patients,  the MC patients were older,  had a more diffi-
cult preoperative diagnosis of malignancy,  a lower rate 
of positive LN,  and high positivity for hormone recep-
tors.  Among these factors,  the reported median age of 
patients with MC has differed among countries,  for 
unknown reasons.  In the SEER database of the U.S.,  
the MC patients (age range 68-75 years) were older than 
the IDC patients (61-53 years) [7 , 8],  whereas in Korea,  
the MC patients were younger (44-45 years) than the 
IDC patients (47 years) [13 , 14].  In the present study,  
the MC patients (mean age 56 years) were older than the 
IDC-NST patients (mean age 53 years),  but the age dif-
ference was smaller than that reported in the U.S.
Regarding the survival rates of MC patients,  in our 
series at a single hospital in Japan,  both the 10-year OS 
(88.3%) and the BSS (93.7%) of the 80 MC patients 
treated during the years 1977-2008 were significantly 
higher than those of the IDC-NST patients (81.6%,  
p = 0.015; 85.0%,  p = 0.005,  respectively).  In 2008,  Di 
Salverio et al.  [7] used the SEER database and observed 
that the 10-year BSS of 11,400 patients with pure muci-
nous breast carcinoma (PMBC) treated during the years 
1973-2002 (89%) was significantly higher than that of 
the IDC patients (72%),  but there was no significant 
difference between these groups in OS.  Fu et al.  used 
[9] the SEER database and the using Life-Table method 
in 2016,  and they reported that the 10-year cancer- 
specific survival rate (CSS) of 3,042 patients with muci-
nous breast cancer (MBC) who were treated in 1990-
2007 (96%) was significantly higher than that of the IDC 
patients (85%).  In 2010 in Korea,  Park et al.  [14] 
reported that the 10-year OS of 104 MC patients treated 
in 1986-2006 (86.3%) was significantly higher than that 
of the patients with IDC-NOS (not otherwise specified) 
(74.9%).  Thus,  although the OS and the BSS of MC and 
IDC-NST patients differed by the period in the above 
three studies,  the MC patients had better prognoses 
compared to IDC-NST patients.
Regarding the prognostic factors of the invasive 
ductal cancer (MC+IDC-NST) patients in the present 
study,  the Cox regression proportional hazards model 
revealed that positive LN metastasis and tumor size 
were strong independent prognostic factors.  MC was 
also an independent better-prognosis factor,  although 
not significantly (HR 0.44,  p = 0.098).  In a large series 
from the SEER database,  MC was an independent fac-
tor for better prognosis based on univariate and multi-
variate analyses [8].  Thus,  MC is a positive indepen-
dent prognostic factor in larger series of patients with 
invasive ductal cancer.
In the present study,  88% of the MC patients had a 
palpable mass.  The frequency of the diagnosis of malig-
nancy based on MG and US was lower in the MC 
patients compared to the IDC-NST patients.  On MG,  
pure MC often presents as a circumscribed lesion 
[15 , 16].  On US,  the cystic appearance of MC may 
make it difficult to determine malignancy.
Regarding the prognostic factors of MC patients in 
the present study,  the univariate analysis revealed that 
the BSS of the MC patients with positive LN metastasis 
was significantly poorer than the BSS of those without 
LN metastasis.  However,  the Cox proportional hazards 
model did not identify predictive factors for the MC 
patients.  Of the 80 patients with MC,  only four patients 
died of breast cancer.  One reason for the insufficient 
information from the Cox proportional hazards model 
is that the incidence of events was and the total number 
of MC patients was small.  The multivariate analysis of a 
large SEER series demonstrated that positive LN metas-
tasis,  poor differentiation,  patient age,  and tumor size 
are independent factors of a poor prognosis in MC 
patients [7 , 8].
In the present series,  15% of the MC patients had 
positive LN metastasis,  and the mean tumor size of the 
MC patients with positive LN metastasis (3.2 cm) was 
significantly larger than that of the MC patient without 
it (1.9 cm).  Using a large contemporary multicenter 
series (111 MC patients,  1997-2004),  Barkley et al.  [4] 
reported that (1) 13% of the MC patients had positive 
LN metastasis,  and (2) node positivity was associated 
with larger tumor size; the patients with positive LN 
metastasis had a significantly larger mean tumor size 
(2.7 cm) compared to that of the patients without LN 
metastasis (1.5 cm).  Their results are consistent with 
ours.  Thus,  the size of the tumor is closely correlated 
with LN metastasis even for MC,  which has a substan-
tial amount of extracellular mucin.  Consequently,  the 
axillary nodal status in MC patients with larger tumors 
should be carefully investigated.
This study has several limitations.  First,  we were 
unable to separate the MC cases by subtype into “pure” 
or “mixed” based on pathology because the slides 
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obtained at our hospital from before 2002 were 
destroyed in the 2002 Tottori western earthquake.  We 
used the breast cancer database of Oomoto Hospital and 
pathological reports; for all 4 patients who died of 
recurrence,  we performed a re-excision from a paraffin 
block of the tumor tissue,  and a pathologist confirmed 
the tumor to be mucinous carcinoma.  A second limita-
tion is that the number of MC patients (n = 80) was too 
small for the identification of definite prognostic pre-
dictors.  A meta-analysis should be performed to evalu-
ate this disease in Japanese patients.
In conclusion,  the prognoses of the MC patients 
were significantly better than those of the IDC-NST 
patients.  The MC patients with positive LN metastasis 
had significantly poorer prognoses compared to those 
without positive LN metastasis.  The tumor sizes of the 
MC patients with positive LN metastasis were signifi-
cantly larger than those of the MC patients without LN 
metastasis.  Although our Cox regression analysis 
revealed no independent factors,  MC patients with pos-
itive LN metastasis should be treated for advanced inva-
sive ductal breast cancer.
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